A case of glycogen storage disease type III (glycogen debranching enzyme deficiency) with liver cirrhosis and hypertrophic cardiomyopathy. 1995

A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
Shounai Amarume Hospital, Japan.

We present a 26-year-old woman with glycogen storage disease type III (debranching enzyme deficiency) complicated with liver cirrhosis and hypertrophic cardiomyopathy. Glycogen debranching enzyme has two catalytic sites, oligo-1,4,-1,4- glucantransferase (EC 2.4.1.25) and amylo-1,6-glucosidase (EC 3.2.1.33). Variability in the clinical phenotype could be a function of the involvement of one or other catalytic site, or differences in tissue expression of the defective enzyme, or both. We hypothesize that some subtypes of glycogen storage disease (GSD) type III may cause liver cirrhosis as seen in GSD type IV due to the accumulation of glycogen of abnormal structure.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006010 Glycogen Storage Disease Type III An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system). The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups Type IIIa and Type IIIb being the most prevalent. Cori's Disease,Debrancher Deficiency,Forbes Disease,Glycogen Debranching Enzyme Deficiency,Glycogenosis 3,Limit Dextrinosis,Amylo-1,6-Glucosidase Deficiency,Cori Disease,Deficiency, Debrancher,Glycogen Debrancher Deficiency,Glycogen Storage Disease III,Glycogen Storage Disease Type 3,Amylo 1,6 Glucosidase Deficiency,Amylo-1,6-Glucosidase Deficiencies,Coris Disease,Debrancher Deficiencies,Debrancher Deficiencies, Glycogen,Debrancher Deficiency, Glycogen,Deficiencies, Amylo-1,6-Glucosidase,Deficiencies, Debrancher,Deficiencies, Glycogen Debrancher,Deficiency, Amylo-1,6-Glucosidase,Deficiency, Glycogen Debrancher,Dextrinoses, Limit,Dextrinosis, Limit,Disease, Cori,Disease, Cori's,Disease, Forbes,Glycogen Debrancher Deficiencies,Glycogenosis 3s,Limit Dextrinoses
D006332 Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES. Cardiac Hypertrophy,Enlarged Heart,Heart Hypertrophy,Heart Enlargement,Cardiac Hypertrophies,Enlargement, Heart,Heart Hypertrophies,Heart, Enlarged,Hypertrophies, Cardiac,Hypertrophies, Heart,Hypertrophy, Cardiac,Hypertrophy, Heart
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
June 1992, Annals of internal medicine,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
February 2012, European heart journal. Cardiovascular Imaging,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
January 1997, Acta cardiologica,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
December 1987, American journal of human genetics,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
January 1990, The Journal of pediatrics,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
January 1993, Heart and vessels,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
May 1963, The Journal of clinical investigation,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
January 1997, Journal of medical genetics,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
January 1998, Ryoikibetsu shokogun shirizu,
A Kobayashi, and F Nishinomiya, and Y Fukamachi, and M Ohtaka, and J Yamamoto, and K Takagi, and S Tanaka, and S Takizawa, and H Imadachi, and M Fukase
August 1996, Biochemical and biophysical research communications,
Copied contents to your clipboard!